Citius Oncology Reports Positive Phase 1 LYMPHIR Data in High-Risk DLBCL, Offering Hope Amidst Going Concern
CTOR sits 94% above its 52-week low of $0.551 on light trading volume (0.2× avg).
Summary
Citius Oncology announced positive topline safety and efficacy results from a Phase 1 trial of LYMPHIR™ (E7777) in high-risk relapsed or refractory DLBCL, showing an 86% overall response rate and good tolerability.
Key Events · Product Development and Regulatory · CTOR
-
Positive Phase 1 Results in DLBCL
LYMPHIR™ (E7777) demonstrated an 86% overall response rate (57% CR, 29% PR) in an investigator-initiated Phase 1 trial for high-risk relapsed or refractory diffuse large B-cell lymphoma (DLBCL) when administered prior to CAR-T therapy.
-
Promising Survival Signals
The trial reported encouraging one-year progression-free survival of 77% and one-year overall survival of 84%, indicating strong early efficacy signals for this difficult-to-treat population.
-
Favorable Safety Profile
LYMPHIR was well-tolerated with no dose-limiting toxicities observed, and reported adverse events were manageable, including effective depletion of regulatory T-cells.
-
New Indication for Approved Drug
LYMPHIR, already FDA-approved for cutaneous T-cell lymphoma (CTCL) and launched in December 2025, is being investigated for this new, high-risk DLBCL population, potentially expanding its market.
Analysis · CTOR · Life Sciences
This announcement of strong preliminary Phase 1 data for LYMPHIR in a new, high-need indication (DLBCL) is highly significant for Citius Oncology, especially given the company's recent disclosure of substantial doubt about its ability to continue as a going concern. While the trial was not powered for efficacy, the reported 86% overall response rate, 77% one-year progression-free survival, and 84% one-year overall survival are very encouraging signals. The positive safety profile, with no dose-limiting toxicities, further supports the drug's potential. This data could be crucial for attracting investment or partnerships, potentially alleviating the immediate financial pressures highlighted in the recent 10-Q and extending the company's operational runway. Investors should monitor further development plans for LYMPHIR in this indication.
How filings like this one have moved
In the 30 days to Sep 20, 2026, 34.7% of the 1039 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.43%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CTOR was trading at $1.07 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $93.6M. The 52-week trading range was $0.55 to $6.19. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.